Basic Information
Twinrix Paediatric
Regulatory Information
EMEA/H/C/000129
February 10, 1997
24
February 7, 2024
Company Information
Belgium
Rue de l'Institut, 89 B-1330 Rixensart
GlaxoSmithKline Biologicals SA
Active Substances Detail
hepatitis A virus (inactivated)hepatitis B surface antigen
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Twinrix Paediatric is indicated for use in non-immune infants, children and adolescents from one year up to and including 15 years who are at risk of both hepatitis-A and hepatitis-B infection.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).